Pulse Biosciences, Inc. PLSE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -21,982.6%— | —— | —— | -8,188.6%— | |
| Net margin | -20,794.6%— | —— | —— | -8,251.8%— | |
| EBITDA margin | -21,675.4%— | —— | —— | -8,005.9%— | |
| Free cash flow margin | -15,553.4%— | —— | —— | -6,687.4%— | |
| Returns | |||||
| Return on equity | -74.4%-7.1pp | -67.3%— | —— | —— | |
| Return on assets | -64.1%-8.2pp | -55.9%+5.7pp | -61.6%+23.8pp | -85.4%+41.4pp | |
| Return on invested capital | -1,168.1%-411pp | -757.1%-338pp | -419.1%+97.8pp | -516.9%-130pp | |
| Efficiency | |||||
| Asset turnover | 0×— | 0×— | 0×0.0× | 0×— | |
| Liquidity | |||||
| Current ratio | 10.5×-1.4× | 11.9×+5.1× | 6.8×-3.6× | 10.4×+3.6× | |
| Quick ratio | 10.5×-1.4× | 11.9×+5.1× | 6.8×-3.6× | 10.4×+4.5× | |
| Cash ratio | 10.2×-1.5× | 11.7×+5.1× | 6.6×-3.6× | 10.2×+3.6× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.1× | 0.2×— | —— | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.1× | 0.2×-0.8× | 1×+0.8× | |
| Interest coverage | -18.4×+2.6× | -21×+11.0× | -31.9×— | —— | |
| Valuation | |||||
| Market capitalization | $930.45M-13.1% | $1.07B+58.9% | $673.91M+553% | $103.12M-76.6% | |
| Enterprise value | $857.24M-10.9% | $961.87M+50.6% | $638.69M+446% | $117.03M-71.2% | |
| Price / sales | 2,658.4×— | —— | —— | 145.5×— | |
| Price / book | 11.5×+2.2× | 9.3×-5.9× | 15.2×— | —— | |
| EV / sales | 2,449.3×— | —— | —— | 165.1×— | |
| Free cash flow yield | -5.9%-2.4pp | -3.4%+1.5pp | -4.9%+41.1pp | -46%-33.6pp | |
| Earnings yield | -7.8%-2.8pp | -5%+1.3pp | -6.3%+50.5pp | -56.7%-42.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pulse Biosciences, Inc.'s profit margins?
- Pulse Biosciences, Inc. (PLSE) runs a -4067.5% gross margin and a -10392.1% operating margin, with a -9929.0% net margin.
- Where do Pulse Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Pulse Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.